![]() |
|
|
Vol. 28, Issue 2, 218-223, February 2000
The Procter & Gamble Company, Miami Valley Laboratories,
Cincinnati, Ohio.
o-Hydroxyphenylacetaldehyde (o-HPA),
the product of coumarin 3,4-epoxide, was synthesized and its
contribution to the hepatotoxic effects of coumarin in the rat was
determined. The relative toxicity of coumarin and o-HPA
were initially assessed in Chinese hamster ovary K1 (CHO K1) cells, a
cell line that does not contain cytochrome P450. In CHO K1 cells,
o-HPA-mediated toxicity greatly exceeded that of
coumarin. CHO K1 cell viability, determined via the reduction of
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT), was decreased by 95 and 6% in cultures containing
o-HPA and coumarin (4 mM), respectively. Coumarin and
o-HPA were then incubated in metabolically competent
primary rat hepatocyte cultures. Cell viability was determined via the
reduction of MTT, and lactic dehydrogenase (LDH) release was used as a
measure of cytotoxicity. Concentration-dependent decreases in cell
viability and increased LDH release were observed using 0.2 to 0.8 mM
o-HPA and coumarin, with coumarin being consistently
less toxic than o-HPA. Cell viability was decreased by
11 and 50% at 0.5 mM coumarin or o-HPA, respectively. Hepatocyte LDH release increased 5-fold after a 6-h exposure to 0.8 mM
o-HPA, corresponding to a greater than 90% loss of cell viability in these cultures. In contrast, 0.8 mM coumarin decreased cell viability by 60%, an effect likely due to the conversion of
coumarin to coumarin epoxide and o-HPA. Furthermore,
3-hydroxycoumarin (0.8 mM), which is not a product of coumarin
epoxidation, had no effect on cell viability or hepatocellular LDH
release. These studies demonstrate that metabolically active rat
hepatocytes convert coumarin into toxic metabolites, and strongly
suggest that o-HPA and coumarin 3,4-epoxide mediate the
toxicity of coumarin in rodents in vivo.
This article has been cited by other articles:
![]() |
T Uehara, N Kiyosawa, T Shimizu, K Omura, M Hirode, T Imazawa, Y Mizukawa, A Ono, T Miyagishima, T Nagao, et al. Species-specific differences in coumarin-induced hepatotoxicity as an example toxicogenomics-based approach to assessing risk of toxicity to humans Human and Experimental Toxicology, January 1, 2008; 27(1): 23 - 35. [Abstract] [PDF] |
||||
![]() |
A. S. Kienhuis, H. M. Wortelboer, J.-C. Hoflack, E. J. Moonen, J. C.S. Kleinjans, B. van Ommen, J. H. M. van Delft, and R. H. Stierum Comparison of Coumarin-Induced Toxicity between Sandwich-Cultured Primary Rat Hepatocytes and Rats in Vivo: A Toxicogenomics Approach Drug Metab. Dispos., December 1, 2006; 34(12): 2083 - 2090. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Vassallo, S. M. Hicks, S. L. Born, and G. P. Daston Roles for Epoxidation and Detoxification of Coumarin in Determining Species Differences in Clara Cell Toxicity Toxicol. Sci., November 1, 2004; 82(1): 26 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Vassallo, S. M. Hicks, G. P. Daston, and L. D. Lehman-McKeeman Metabolic Detoxification Determines Species Differences in Coumarin-Induced Hepatotoxicity Toxicol. Sci., August 1, 2004; 80(2): 249 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Born, D. Caudill, B. J. Smith, and L. D. Lehman-McKeeman In Vitro Kinetics of Coumarin 3,4-Epoxidation: Application to Species Differences in Toxicity and Carcinogenicity Toxicol. Sci., November 1, 2000; 58(1): 23 - 31. [Abstract] [Full Text] [PDF] |
||||